(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN

Objective: Sarcomas are cancers that originate in the bones or soft parts of the body. According to data collected by the Spanish Sarcoma Research Group (GEIS), these diseases do not exceed 1% of all cancers diagnosed in Europe. Like any cancer diagnosis, sarcomas generate emotional impact and distress in patients and their families, affecting their quality of life in multiple dimensions. Hospital Clinico san Carlos is a national referral centre for sarcomas in Spain and our sarcoma MDT has recently incorporated two psychologists within sarcoma clinics to improve sarcoma care.

Objectives: To evaluate the levels of anxiety, depression, quality of life, acceptance of the disease and their relationship with sociodemographic and clinical variables in patients with sarcoma.

Methods: The ongoing study has a cross-sectional correlational descriptive design expecting to recruit 124 subjects (started in March 2023). Selection criteria: patients treated at Hospital Clínico San Carlos in Madrid, ≥ 18 years of age, able to read and write in Spanish. Patients with a history of psychopathological disorder were excluded.
Independent variables studied were the following: age, sex, marital status, employment and educational situation, subtype of sarcoma, stage and treatments received, evaluated by sociodemographic questionnaire. Symptoms of anxiety and depression were assessed with the Hospital Anxiety and Depression Scale (HAD-A and HADS-D), quality of life with the EORTC QLQ-C30, and the Illness Acceptance Questionnaire. The data was collected online and in person.

Results: 34 patients have accepted to participate from March 2023 so far, 50% of which were men; mean age =51.5 years SD= 14.9, range: 21-81); disease stage I according to TNM 2019:: 31%; II: 31%; III: 25% stage IV: 12.5%.
The most relevant data encountered have been so far/ The most relevant findings have been so far :
The level of acceptance of the disease was high: 34.5 (SD= 6.87), 95%CI= 32-37.
HADS-A= 7.34 (SD= 4.39) 95%CI=5.86-8.93) HADS-D= 5.18 (SD= 4.01), 95%CI=3.72-6, 65). 39% present clinical or subclinical anxiety symptoms and 26% clinical or subclinical depression symptoms.
The results in terms of quality of life are as follows:
Global QLQ-C30: 66.14 (SD= 23.94) 95%CI=57.251-74.78); QLQ-C30 Global F. Physics: 77.62 (SD=24.28) 95%CI= 66.87-84.38; QLQ-C30 F. Role: 72.92 (SD=31.32) 95%CI= 61.2-684); QLQ-C30 F. Emotional: 65.62 (SD=27.58) ) 95%CI=55.7-75.57; QLQ-C30 F. Cognitive: 76.5625 (SD=28.04) 95%CI=66.45-86.67; QLQ-C30 Social F.: 70.83 (SD=29.63) 95%CI=60.15-81.52. The symptoms with the highest means in the QLQ-C30 have been fatigue: 43.0556 (SD=34.88) 95%CI=30.48-55.63); Pain: 35.42 (SD=35.36) 95%CI=22.67-48.16); Insomnia 40.63 (SD=35.66) 95%CI=22.677-53.48).
The patients who received chemotherapy presented lower acceptance (p=0.003), higher levels of depressive symptoms (p=0.001); scored worse in QLQ-C30 in F. Role (p=0.005) emotional (p=0.034) F. Cognitive (p= 0.3021), as well as in fatigue p=0.024)
The acceptance variable was highly correlated with HAD-A (r=-0.53) and HADS-D (r=0.55) and showed correlations greater than 0.4 in all dimensions of the QLQC-30.

Conclusion: The intervention has detected high levels of anxiety, depression and quality of life problems in sarcoma patients so far, despite the small size to date. Acceptance scale shows a high reliability, and it is predictive of anxiety, depression and quality of life impairment. Type of treatments influence these parameters, being chemotherapy the treatment with a worse impact on the patient's psychological sphere. These preliminary data highlight the need for comprehensive care for patients with sarcoma mainly psychological assessment and intervention.